Positive News SentimentPositive NewsNYSE:PEN Penumbra (PEN) Stock Price, News & Analysis $327.34 +0.79 (+0.24%) Closing price 03:59 PM EasternExtended Trading$327.38 +0.05 (+0.01%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Penumbra Stock (NYSE:PEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Penumbra alerts:Sign Up Key Stats Today's Range$325.13▼$327.6950-Day Range$321.64▼$338.6552-Week Range$221.26▼$362.41Volume449,745 shsAverage Volume841,233 shsMarket Capitalization$12.87 billionP/E Ratio75.42Dividend YieldN/APrice Target$361.33Consensus RatingHold Company Overview Penumbra, Inc. is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world. At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. The company also offers embolization coil systems and flow-diversion devices for the treatment of cerebral aneurysms and vascular lesions. In its peripheral vascular line, Penumbra markets aspiration thrombectomy systems and small-vessel clot retrieval tools designed for limb salvage and treatment of pulmonary embolism. Founded in 2004 by engineer Arani Bose, Penumbra launched its first commercial thrombectomy product in 2007 and has since expanded into new geographies and indications. The company maintains its headquarters in Alameda, California, with additional operations in Europe and Asia Pacific. Over the years, Penumbra has invested in R&D facilities and regulatory approvals to support product launches across more than 100 countries. Under the leadership of President and Chief Executive Officer Adam Elsesser, Penumbra continues to advance its pipeline of next-generation devices, focusing on catheter design, clot visualization and real-time feedback technologies. The company collaborates with academic institutions and clinical specialists to refine procedural techniques and drive evidence generation in stroke and vascular care.AI Generated. May Contain Errors. Read More Penumbra Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScorePEN MarketRank™: Penumbra scored higher than 72% of companies evaluated by MarketBeat, and ranked 226th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingHold Consensus RatingPenumbra has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 3 buy ratings, 14 hold ratings, and no sell ratings.Upside PotentialPenumbra has a consensus price target of $361.33, representing about 10.4% upside from its current price of $327.25.Amount of Analyst CoveragePenumbra has only been the subject of 3 research reports in the past 90 days.Read more about Penumbra's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth26.57% Earnings GrowthEarnings for Penumbra are expected to grow by 26.57% in the coming year, from $5.08 to $6.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Penumbra is 75.39, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Penumbra is 75.39, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.71.Price to Earnings Growth RatioPenumbra has a PEG Ratio of 2.00. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPenumbra has a P/B Ratio of 8.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Penumbra's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.97% of the float of Penumbra has been sold short.Short Interest Ratio / Days to CoverPenumbra has a short interest ratio ("days to cover") of 3.28, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Penumbra has recently decreased by 5.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPenumbra does not currently pay a dividend.Dividend GrowthPenumbra does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment1.71 News SentimentPenumbra has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Penumbra this week, compared to 5 articles on an average week.Search Interest2 people have searched for PEN on MarketBeat in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $865,296.00 in company stock.Percentage Held by Insiders2.90% of the stock of Penumbra is held by insiders.Percentage Held by Institutions88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Penumbra's insider trading history. Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PEN Stock News HeadlinesPenumbra, Inc. (NYSE:PEN) Given Average Rating of "Hold" by BrokeragesMay 12, 2026 | americanbankingnews.comCitigroup Cuts Penumbra (NYSE:PEN) Price Target to $350.00May 10, 2026 | americanbankingnews.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)Assessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E MultipleMay 7, 2026 | finance.yahoo.comPenumbra: Q1 Earnings SnapshotMay 6, 2026 | chron.comPenumbra, Inc. Reports First Quarter 2026 Financial ResultsMay 6, 2026 | prnewswire.comInside Boston Scientific's $15 billion offer for Alameda's largest employerMay 2, 2026 | bizjournals.comRBC Capital Remains a Hold on Penumbra (PEN)April 17, 2026 | theglobeandmail.comSee More Headlines PEN Stock Analysis - Frequently Asked Questions How have PEN shares performed this year? Penumbra's stock was trading at $311.45 at the beginning of 2026. Since then, PEN shares have increased by 5.1% and is now trading at $327.2540. How were Penumbra's earnings last quarter? Penumbra, Inc. (NYSE:PEN) issued its earnings results on Wednesday, May, 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.06 by $0.24. The business's quarterly revenue was up 15.6% on a year-over-year basis. How will Penumbra's stock buyback program work? Penumbra's Board of Directors authorized a share buyback program on Tuesday, August 13th 2024, which permits the company to repurchase $200,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 2.6% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's leadership believes its stock is undervalued. When did Penumbra IPO? Penumbra (PEN) raised $106 million in an IPO on Friday, September 18th 2015. The company issued 4,000,000 shares at $25.00-$28.00 per share. Who are Penumbra's major shareholders? Penumbra's top institutional shareholders include Whitebox Advisors LLC (1.13%), Arrowstreet Capital Limited Partnership (1.02%), Amundi (0.88%) and Dimensional Fund Advisors LP (0.83%). Insiders that own company stock include Arani Bose, Adam Elsesser, Johanna Roberts, Lambert Shiu, Maggie Yuen, Harpreet Grewal, Bridget O'rourke, Surbhi Sarna, Don W Kassing and Thomas Wilder. View institutional ownership trends. How do I buy shares of Penumbra? Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Penumbra own? Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW), Adobe (ADBE) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/06/2026Today5/20/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PEN's financial health is in the Green zone, according to TradeSmith. PEN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSE:PEN CIK1321732 Webwww.penumbrainc.com Phone(510) 748-3200Fax510-748-3232Employees4,700Year Founded2004Price Target and Rating Average Price Target for Penumbra$361.33 High Price Target$388.00 Low Price Target$266.00 Potential Upside/Downside+10.4%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$4.34 Trailing P/E Ratio75.42 Forward P/E Ratio64.44 P/E Growth2Net Income$177.69 million Net Margins11.76% Pretax Margin13.96% Return on Equity10.87% Return on Assets8.45% Debt Debt-to-Equity Ratio0.01 Current Ratio6.02 Quick Ratio3.95 Sales & Book Value Annual Sales$1.40 billion Price / Sales9.17 Cash Flow$4.31 per share Price / Cash Flow75.96 Book Value$37.47 per share Price / Book8.74Miscellaneous Outstanding Shares39,330,000Free Float38,190,000Market Cap$12.87 billion OptionableOptionable Beta0.74 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:PEN) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
